Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D.
Journal: The New England journal of medicine
Published: November 10, 2025
Longer-Term Clinical Outcomes From the THINKER and EXPANDER Trials of Transplantation of HCV-RNA+ Donor Kidneys Into Hepatitis C Virus-Negative Recipients.
Journal: Kidney international reports
Published: February 06, 2023
Design principles for inflammasome inhibition by pyrin-only-proteins.
Journal: eLife
Published: July 15, 2022
Cross-reactive antibodies facilitate innate sensing of dengue and Zika viruses.
Journal: JCI insight
Published: June 09, 2021
Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis C-Viremic Donors to Hepatitis C-Negative Recipients: An Open-Label Nonrandomized Study.
Journal: Annals of internal medicine
Published: September 07, 2020
Where do plasmacytoid dendritic cells find the energy?
Journal: Journal of leukocyte biology
Published: June 03, 2020
Allosteric coupling between Mn2+ and dsDNA controls the catalytic efficiency and fidelity of cGAS.
Journal: Nucleic acids research
Published: December 09, 2019
Assessment of inflammasome and type I IFN responses to DNA viruses and DNA PAMPS.
Journal: Methods in enzymology
Published: August 29, 2019
Lessons from the real world: HCV-infected donor kidney transplantation as standard practice.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Published: July 28, 2019
Bypassing the bottleneck: intentional hepatitis C transmission with organ transplant.
Journal: The Journal of clinical investigation
Published: June 25, 2019
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
Journal: Annals of internal medicine
Published: March 07, 2018
CMPK2 and BCL-G are associated with type 1 interferon-induced HIV restriction in humans.
Journal: Science advances
Published: January 22, 2018
Last Updated: 09/26/2026